Try
Edwards Lifesciences Corp
EWUnited States
71 filed reports · 631 financial concepts · 41 earnings calls · 3 media appearances
Filed reports
71 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 264 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 6,757 | Jun 2016 to Jun 2026 |
| Current · 8-KSEC EDGAR | 30 | 260 | Mar 2019 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 7,042 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 559 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 23, 2026 | 16 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 343 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 23, 2026 | 14 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 25, 2026 | 1,449 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 10, 2026 | 12 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 388 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 30, 2025 | 8 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 229 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 24, 2025 | 10 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 6, 2025 | 231 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | Apr 23, 2025 | 12 | Open |
Financial data
631 concepts · 14,059 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial612 concepts · 12,649 facts · Dec 2014 to Jul 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Gross profit (US GAAP)58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Allocated share based compensation expense57 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Cost of goods and services sold (US GAAP)57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Other comprehensive income loss foreign currency transaction and translation adjustment net of tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent57 · Dec 2014 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax57 · Dec 2014 to Jun 2026
- Research and development expense57 · Dec 2014 to Jun 2026
- Selling general and administrative expense57 · Dec 2014 to Jun 2026
- Capital expenditures incurred but not yet paid56 · Dec 2014 to Jun 2026
- Depreciation depletion and amortization56 · Dec 2014 to Jun 2026
- Increase decrease in accounts and other receivables56 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities56 · Dec 2014 to Jun 2026
- Increase decrease in accrued income taxes payable56 · Dec 2014 to Jun 2026
- Increase decrease in deferred income taxes56 · Dec 2014 to Jun 2026
- Increase decrease in inventories56 · Dec 2014 to Jun 2026
- Increase decrease in other operating capital net56 · Dec 2014 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets56 · Dec 2014 to Jun 2026
- Other noncash income expense56 · Dec 2014 to Jun 2026
- Other nonoperating income expense56 · Dec 2014 to Jun 2026
- Payments for proceeds from other investing activities56 · Dec 2014 to Jun 2026
Segment10 concepts · 696 facts · Dec 2014 to Jun 2026
- Revenue226 · Dec 2014 to Jun 2026
- Income loss from continuing operations before income taxes minority interest and income loss from equity method investments184 · Dec 2014 to Jun 2026
- Cost of goods and services sold (US GAAP)56 · Dec 2022 to Jun 2026
- Segment reporting other item amount56 · Dec 2022 to Jun 2026
- Selling general and administrative expense56 · Dec 2022 to Jun 2026
- Goodwill foreign currency translation gain loss41 · Dec 2015 to Dec 2025
- Goodwill31 · Dec 2015 to Dec 2025
- Goodwill acquired during period23 · Dec 2015 to Dec 2024
- Revenue (excluding assessed tax)20 · Dec 2023 to Jun 2026
- Goodwill purchase accounting adjustments3 · Dec 2025
Guidance6 concepts · 260 facts · Apr 2019 to Jul 2026
- EPS (Diluted) Guidance106 · Apr 2019 to Jul 2026
- Revenue Guidance100 · Apr 2019 to Jul 2026
- Revenue Growth Guidance34 · Apr 2021 to Jul 2026
- Gross Margin Guidance10 · Oct 2024 to Jul 2026
- Operating Margin Guidance8 · Apr 2025 to Jul 2026
- Effective Tax Rate Guidance2 · Jul 2026
Product2 concepts · 238 facts · Dec 2014 to Jun 2026
- Revenue228 · Dec 2014 to Jun 2026
- Cost of goods and services sold (US GAAP)10 · Dec 2016 to Dec 2025
Geography1 concepts · 216 facts · Dec 2014 to Sep 2024
- Revenue216 · Dec 2014 to Sep 2024
Segments
1,150 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments7 members · 696 facts
- Europe168 · Dec 2014 to Jun 2026
- United States168 · Dec 2014 to Jun 2026
- Rest Of World165 · Dec 2014 to Jun 2026
- Japan144 · Dec 2014 to Jun 2026
- Europe segment21 · Dec 2015 to Jun 2026
- Rest of world segment19 · Dec 2017 to Jun 2026
- United states segment11 · Dec 2015 to Dec 2025
Product or servicesrt:ProductOrServiceAxis7 members · 190 facts
- Surgical Heart Valve Therapy45 · Dec 2016 to Dec 2025
- Transcatheter Mitral And Tricuspid Therapies43 · Dec 2017 to Jun 2026
- Transcatheter Aortic Valve Replacement42 · Mar 2018 to Jun 2026
- Critical Care36 · Dec 2016 to Mar 2024
- Shipping And Handling10 · Dec 2016 to Dec 2025
- Transcatheter Heart Valves10 · Dec 2016 to Dec 2019
- Surgical4 · Mar 2025 to Jun 2026
Statement geographicalsrt:StatementGeographicalAxis4 members · 152 facts
- Europe38 · Dec 2016 to Sep 2024
- JP38 · Dec 2016 to Sep 2024
- Rest Of World38 · Dec 2016 to Sep 2024
- US38 · Dec 2016 to Sep 2024
Statement geographicalus-gaap:StatementGeographicalAxis4 members · 64 facts
- Europe16 · Dec 2014 to Mar 2018
- JP16 · Dec 2014 to Mar 2018
- Rest Of World16 · Dec 2014 to Mar 2018
- US16 · Dec 2014 to Mar 2018
Product or serviceus-gaap:ProductOrServiceAxis3 members · 48 facts
- Critical Care16 · Dec 2014 to Mar 2018
- Surgical Heart Valve Therapy16 · Dec 2014 to Mar 2018
- Transcatheter Heart Valves16 · Dec 2014 to Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary135 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary165 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes9 claims from 1 reports · Dec 2025
- Risk factors51 risks from 2 annual reports · 2024 to 2025
Earnings calls
41 calls · Jul 2016 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 23, 2026
- FY2026 Q1Apr 23, 2026
- FY2025 Q4Feb 10, 2026
- FY2025 Q3Oct 30, 2025
- FY2025 Q2Jul 24, 2025
- FY2025 Q1Apr 23, 2025
- FY2024 Q4Feb 11, 2025
- FY2024 Q3Oct 24, 2024
- FY2024 Q2Jul 24, 2024
- FY2024 Q1Apr 25, 2024
- FY2023 Q4Feb 6, 2024
- FY2023 Q3Oct 26, 2023
- FY2023 Q2Jul 26, 2023
- FY2023 Q1Apr 26, 2023
- FY2022 Q4Jan 31, 2023
- FY2022 Q3Oct 27, 2022
Executive media
3 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances1 · Jun 2025
- Podcasts1 · Aug 2025
- TV interviews1 · Dec 2021
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.